Perspective: Effect of rosiglitazone on cardiovascular outcomes

Current Cardiology Reports

Volumn 9, Issue 5, 2007, Pages 343-344

  Nissen, Steven E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MURAGLITAZAR; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE;

ANEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIABETES CONTROL; DIABETIC PATIENT; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GENE ACTIVATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HUMAN; INCIDENCE; MICROANGIOPATHY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OUTCOME ASSESSMENT; POSTMARKETING SURVEILLANCE; RISK ASSESSMENT; RISK FACTOR;

CARDIOVASCULAR DISEASES; HUMANS; HYPOGLYCEMIC AGENTS; MYOCARDIAL INFARCTION; ODDS RATIO; PPAR GAMMA; RISK ASSESSMENT; THIAZOLIDINEDIONES;

EID: 34548413692     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02938358     Document Type: Note

References (5)

1. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
2. Bradburn MJ, Deeks JJ, Berlin JA, Localio AR: Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007, 2653-77.
3. Avandia [package insert]. Philadelphia, PA: GlaxoSmithKline; 2007. Available at http://www.fda.gov/cder/foi/label/2007/021071s023lbl.pdf. Accessed May 15, 2007.
4. Nissen SE, Wolski K, Topol EJ: Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005, 294:2581-2586.
5. Dormandy JA, Charbonnel B, Eckland DJ, et al.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.